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Abstract
During normal sympathetic nervous system (SNS) development, cells of the ganglionic lineage can malignantly trans-
form and develop into the childhood tumor neuroblastoma. Hypoxia-inducible transcription factors (HIFs) mediate
cellular responses during normal development and are central in the adaptation to oxygen shortage. HIFs are also
implicated in the progression of several cancer forms, and high HIF-2α expression correlates with disseminated dis-
ease and poor outcome in neuroblastoma. During normal SNS development, HIF2A is transiently expressed in neuro-
blasts and chromaffin cells. SNS cells can, during development, be distinguished by distinct gene expression patterns,
and insulin-like growth factor 2 (IGF2) is a marker of sympathetic chromaffin cells, whereas sympathetic neuroblasts
lack IGF2 expression. Despite the neuronal derivation of neuroblastomas, we show that neuroblastoma cell lines and
specimens express IGF2 and that expression of HIF2A and IGF2 correlates, with the strongest correlation in high-
stage tumors. In neuroblastoma, both IGF2 andHIF2A are hypoxia-driven and knocking down IGF2 at hypoxia resulted
in downregulatedHIF2A levels. HIF-2α and IGF2were strongly expressed in subsets of immature neuroblastoma cells,
suggesting that these two genes could be co-expressed also at early stages of SNS development. We show that IGF2
is indeed expressed in sympathetic chain ganglia at embryonic week 6.5, a developmental stage when HIF-2α is pres-
ent. These findings provide a rationale for the unexpected IGF2 expression in neuroblastomas and might suggest that
IGF2 and HIF2A positive neuroblastoma cells are arrested at an embryonic differentiation stage corresponding to the
stage when sympathetic chain ganglia begins to coalesce.
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Introduction
Neural crest–derived sympathoadrenal precursor cells give rise to three
different lineages during development: the ganglionic, adrenal/extra-
adrenal chromaffin, and small intensely fluorescent (SIF) cell lineages
[1]. The childhood tumor neuroblastoma is derived from immature
cells of the ganglionic sympathetic nervous system (SNS) lineage,
and tumors can arise at any site where sympathetic neuroblasts are
present during normal development [2]. Neuroblastomas are clinically
subdivided into stages 1 to 4, where the stage 4 tumors present with
disseminated disease and are generally high-risk tumors with poor prog-
nosis. There is also a strong correlation between high-risk tumors and
an immature tumor cell phenotype [3].
Neuroblastoma cells cultured under hypoxic conditions lose their
differentiated phenotype and acquire stem cell–like features [4], pre-
sumably contributing to the general finding that hypoxic solid tumors
Abbreviations: HIF, hypoxia-inducible factor; IGF, insulin-like growth factor; SIF,
small intensely fluorescent; SNS, sympathetic nervous system
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are more aggressive [5,6]. In particular, high expression of hypoxia-
inducible factor 2α (HIF-2α) protein correlates to poor prognosis
and high clinical stage in neuroblastoma [7,8]. In addition, peri-
vascularly located neuroblastoma cells intensely staining for HIF-2α
have an immature stem cell–like phenotype [9]. HIF2A is selectively
and transiently expressed during discrete periods of normal murine
and human SNS development [10,11] and deletion of HIF2A in
129/SvJ mice leads to severe impairment of the development of SNS
structures [11]. Interestingly, in paraganglioma, another SNS-derived
tumor, somatic HIF2A gain-of-function mutations were recently de-
scribed [12], suggesting a role of HIF-2 in SNS cell tumorigenesis.
The HIF-2 transcription factor is part of the cellular adaptation ma-
chinery activated at oxygen shortage. Mammalian cells adapt to
hypoxia by activating a transcriptional program mainly orchestrated
by the dimeric HIF-1, HIF-2, and HIF-3. The HIF-α subunits are
typically degraded at physiological oxygen concentrations but are
stabilized at hypoxia and can then form transcriptionally active
complexes [13,14]. Thus, HIFs are generally not considered to be
regulated at the transcriptional level by oxygen shortage. However,
here we show that hypoxia transcriptionally upregulates HIF2A in
neuroblastoma cells.
HIF transcription is known to be regulated by growth factors in
presumably a cell context–dependent manner [15]. In search for growth
factors that are upregulated by hypoxia in neuroblastoma, insulin-like
growth factor II (IGF-II) was one candidate, as it is frequently induced
in perinecrotic and hypoxic areas of neuroblastoma specimens [16] and
in neuroblastoma cells exposed to long-term hypoxia [4]. Here, we
show that IGF2 and HIF2A mRNA expression is induced in neuro-
blastoma cells during hypoxic conditions. We further demonstrate
a positive correlation between IGF2 and HIF2A expression in a clini-
cal neuroblastoma material, and knocking down IGF2 expression in
hypoxic neuroblastoma cells results in diminished HIF2A expression.
As IGF2 is a marker of sympathetic chromaffin and SIF cell differ-
entiation and is not expressed in neuroblasts [2,16], we reinvestigated
the expression of HIF-2α and IGF2 during normal human SNS de-
velopment. We found that IGF2 indeed is expressed in embryonic
(week 6.5) human sympathetic neuroblasts, a time point when HIF-2α
expression still persists. This observation together with our in vitro
data suggests that IGF-II regulates HIF2A expression in neuro-
blastoma and during discrete and short phases of SNS development.
Materials and Methods
Tissues and Cells
Human embryonic and fetal tissue was obtained at either elective
(week 6.5 embryo) or spontaneous (week 12) abortions [Ethical
approvals LU 389-98 (Lund University) and 93-216 (Karolinska
Hospital, Stockholm, Sweden)]. Routinely fixed paraffin-embedded
human neuroblastoma specimens were used (Ethical permit LU 389-98).
Immunohistochemical staining and in situ hybridization were per-
formed as described previously [2,16]. Antibodies used were mouse
anti–HIF-2α (Novus Biologicals, Littleton, CO) and rabbit anti-tyrosine
hydroxylase (TH; Abcam, Cambridge, United Kingdom). The human
neuroblastoma cell lines SK-N-BE(2)c, IMR-32, and KCN-69n (kind
gifts from Dr June Biedler, Memorial Sloan Kettering Cancer Institute
and Dr Robert Ross, Fordham University) were cultured in minimal
essential or RPMI 1640 (IMR-32) medium supplemented with FBS
and antibiotics. As part of our laboratory routines, all cell lines were reg-
ularly screened for mycoplasma and replaced by low-passage cells on a
trimonthly basis. Transfection of SK-N-BE(2)c cells was performed
using three small interference RNAs (siRNAs) targeting IGF2 or a non-
targeting control siRNA (all from Selleckchem, Munich, Germany)
at concentrations of 50 nM with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) as transfection reagent. KCN-69n cells were nucleo-
fected with 2 μg of either siRNA using Amaxa Cell Line Nucleofector
Kit V (Lonza, Köln, Germany) according to the manufacturer’s
instructions (Nucleofector Program A-023). Hypoxia was generated
in a Whitley H35 Hypoxystation (Don Whitley Scientific, Shipley,
United Kingdom).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) after homogenizing cells using the QIAshredder
Kit (Qiagen) according to the manufacturer’s recommendation. RNA
was DNAse treated and washed (Millipore Amicon Ultra Centrifugal
Filter Units). cDNA synthesis was performed using MultiScribe
Reverse Transcriptase enzyme (Applied Biosystems, Foster City, CA)
together with random primers. Quantitative polymerase chain reaction
(PCR) analysis was performed in a 7300 Real-Time PCR System
(Applied Biosystems) using SYBR Green PCR Master Mix (Applied
Biosystems), and the comparative C t method to quantify relative
mRNA was used. Expression levels of three housekeeping genes
(YWHAZ, SDHA, and UBC) were used to normalize gene-of-interest
expression [17]. Primer sequences are listed in Table W1.
Enzyme-Linked Immunosorbent Assay
Secreted (supernatant) and intracellular (whole-cell lysate) IGF-II
protein was measured by ELISA (human IGF-II ELISA; Mediagnost,
Reutlingen, Germany) according to the manufacturer’s recommen-
dation. Cells were cultured at 21% or 1% oxygen for 72 hours and
supernatant was collected and kept at −20°C until ELISA was run.
Samples were centrifuged at 1500 rpm before use to remove cell debris.
For whole-cell lysates, cells were lysed in NP-40 buffer [150 mMNaCl,
50 mM Tris-Cl (pH 7.4), 1 mM EDTA (pH 8.0), 1% Igepal] sup-
plemented with complete protease inhibitor (Roche, Indianapolis,
IN), and whole protein content was determined using Bradford (Pierce,
Rockford, IL). IGF-II protein concentrations were calculated using
four-parameter non-linear regression.
Animal Procedures
Female athymic mice (NMRI-Nu/Nu strain; Taconic, Lille Skensved,
Denmark) were housed in a controlled environment and all procedures
were approved by the regional ethics committee for animal research
(Approval No. M299-10). KCN-69n cells (1 × 105–8 × 105) were
prepared in 30 μl of Matrigel/Hank’s balanced salt solution (2:1). Mice
were anesthetized by isoflurane inhalation. Surgical exposure of the left
adrenal glandwas achieved by temporal displacement of the spleen.Using
a 29-ga. needle, cells were injected into the left adrenal gland fat pad
and the skin was closed using surgical clips [18]. Mice were sacrificed
4 weeks after injection and tumors were snap-frozen for further analysis.
Statistical Analyses
All values presented in this study are reported as means ± SEM from
three independent experiments. Two-sided Student’s unpaired t test was
used for statistical analyses (*P < .05, **P < .01, and ***P < .001). A
publicly available data set containing 88 neuroblastomas [R2: microarray
analysis and visualization platform (http://r2.amc.nl)] was used to analyze
Pearson’s correlation between IGF2 and HIF2A expression.
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Figure 1. HIF2A and IGF2 correlate and are co-expressed in neuroblastoma specimen. (A) Quantitative real-time–PCR (qRT-PCR) analy-
sis of HIF2A mRNA expression in SK-N-BE(2)c, KCN-69n, and IMR-32 cells cultured for 72 hours at 21% or 1% oxygen. (B) qRT-PCR
analysis of IGF2 mRNA expression in cells cultured for 72 hours at 21% or 1% oxygen. (C) Secreted IGF-II protein levels detected in
conditioned medium by human IGF-II ELISA. (D) Intracellular IGF-II protein levels detected by human IGF-II ELISA. (A–D) Data are presented
as means ± SEM from three independent experiments; P values were calculated using Student’s t test (*P < .05, **P < .01, and ***P <
.001). (E) HIF2A and IGF2 gene expression correlation in a data set containing 88 neuroblastoma tumors (Versteeg-88-MAS5.0-u133p2).
(F) HIF2A and IGF2 gene expression correlation in the subgroup of MYCN-amplified tumors from the data set used in D. (G) HIF2A and
IGF2 gene expression correlation in the subgroup of non–MYCN-amplified tumors from the data set used in D. (H) HIF2A and IGF2 gene
expression correlation in the subgroup of International Neuroblastoma Staging System (INSS) stage 4 tumors from the data set used in D.
(I) HIF2A and IGF2 gene expression correlation in the joint subgroup of INSS stage 1 to 3 tumors from the data set used in D. (E–I) R value
was calculated using Pearson correlation and n is equal to the number of tumors in each subset. (J) Levels of IGF2 and HIF2A mRNA ex-
pression in orthotopic neuroblastoma tumors as measured by qRT-PCR. KCN-69n neuroblastoma cells were grown at 21% O2 for 24 hours
before transplantation into the adrenal gland fat pad of NMRI-Nu/Nu mice. Tumors were excised 4 weeks after cell implantation. Gene
expression levels in KCN-69n cells cultured in vitro at 21% or 1% O2 for 72 hours were used as comparison. (K–M) Immunohistochemical
TH (K) and HIF-2α (M) staining and IGF-II in situ hybridization (L) of a neuroblastoma specimen. Asterisk indicates a blood vessel. Scale bars
represent 50 μm.
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Results
HIF2A and IGF2 Expression Correlates in Neuroblastoma
Cells and Tumor Specimens
HIF2A is expressed in most neuroblastoma cell lines and mRNA
levels are induced at hypoxia (1% O2) [7,19], as exemplified by SK-N-
BE(2)c and KCN-69n cells (Figure 1A). The IMR-32 neuroblastoma
cell line is an exception and lacksHIF2AmRNA and protein expression
both at normoxia and hypoxia (Figure 1A and [4,20]). The mech-
anisms regulating normoxic and hypoxic HIF2A expression are poorly
defined, but growth factors are known to be able to stimulate the ex-
pression and translation of bothHIF1A and HIF2A (reviewed in [15]).
A few of these factors are hypoxia-driven and IGF-II is one example in
neuroblastoma. Interestingly, while the IGF2 expressing SK-N-BE(2)c
and KCN-69n cells further increased their expression of IGF2 at hyp-
oxia, IMR-32 cells had barely detectable expression independent of
oxygen levels (Figure 1B). Thus, IMR-32 cells virtually lack expression
of both HIF2A and IGF2. The expression pattern of IGF2mRNA was
reflected at the protein level as measured by ELISA (Figure 1, C and
D). Notably, IMR-32 cells had extremely low (secreted protein) or even
undetectable (cell lysates) IGF-II levels irrespective of oxygen pressure
(Figure 1, C and D). The expression of HIF2A and IGF2 mRNA
persisted when KCN-69n cells were grown as orthotopic xenografts
(Figure 1J ).
Mining a publicly available clinical neuroblastoma expression data set
[R2: microarray analysis and visualization platform (http://r2.amc.nl)]
further revealed a strong correlation between IGF2 and HIF2A expres-
sion in a clinical material of 88 well-defined neuroblastoma specimens
(R = 0.49; Figure 1E ). In this material, 87 of 88 tumors presented
with an IGF2 signal, while all 88 tumors had robust HIF2A ex-
pression. In light of the recent report by Qing et al. [21], proposing
that HIF2A is not expressed in MYCN-amplified neuroblastoma
cells, we subdivided the expression data into an MYCN-amplified and
a non–MYCN-amplified group. As shown in Figure 1, F and G ,
MYCN-amplified tumors express HIF2A and the correlation between
IGF2 and HIF2A expression persists and is even stronger in MYCN-
amplified compared to non-amplified tumors (R = 0.59 and R = 0.48,
respectively). To test the potential association between HIF2A and
IGF2mRNA expression and aggressive disease, the data set was divided
into stage 4 versus stage 1 to 3 tumors. This revealed a strong correlation
between HIF2A and IGF2 expression in stage 4 tumors (R = 0.69;
Figure 1H ), while the correlation was substantially weaker in stage 1
to 3 tumors (R = 0.33; Figure 1I).
Collectively, our data indicate that the expression of IGF2 and
HIF2A is interrelated. This is further supported by our previous ob-
servation [9] that human neuroblastoma tumors often contain imma-
ture, stem cell–like neuroblastoma cells that have high HIF-2α as well
as high IGF2 expression as exemplified in Figure 1, L and M . These
cells typically lack expression of neuronal sympathetic differentiation
marker genes such as TH (Figure 1K ) and neuron-specific enolase
and are often located in perivascular niches [9]. These and published
in vivo data [10,11] further indicate that HIF-2α protein in developing
Figure 2. IGF-II regulates HIF2A mRNA expression at hypoxia. (A) Expression of HIF2A and HIF-2–driven gene SERPINB9 mRNA after
down-regulation of IGF2 in SK-N-BE(2)c and KCN-69n cells using three different siRNAs targeting the IGF2 gene at normoxia (21% O2),
as measured by qRT-PCR. (B) Expression of HIF2A and SERPINB9 mRNA after down-regulation of IGF2 in SK-N-BE(2)c and KCN-69n
cells using three different siRNAs targeting the IGF2 gene at hypoxia (1% O2), as measured by qRT-PCR. Data are presented as means ±
SEM from three independent experiments, and mRNA expression after IGF2 knockdown is normalized against siC within each exper-
iment. Statistical significance is calculated compared to siC using Student’s t test (*P < .05, **P < .01, and ***P < .001).
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and malignant sympathetic structures is not efficiently degraded under
oxygenated conditions.
HIF2A Is Transcriptionally Regulated by IGF-II in
Neuroblastoma Cells
HIF-2 is a transcription factor normally stabilized and activated
under hypoxic conditions, but in vivo data suggest that HIF-2α,
the oxygen sensitive and degradable HIF-2 subunit, might be active
also in contexts of physiological oxygen tensions [4,7,10]. Under
in vivo conditions, HIF2A expression is distinctly and transiently regu-
lated during SNS development. To test if IGF-II could be one factor
regulating the transcription of HIF2A in neuroblastoma cells, IGF2
expression was downregulated using three different siRNAs (Figure 2,
A and B). At normoxia, a slight decrease of HIF2A mRNA was noted,
whereas expression of the HIF-2α–driven gene SERPINB9 was virtually
unaffected by IGF2 knockdown (Figure 2A). At hypoxia however,
Figure 3. IGF-II expression is absent in human fetal sympathetic ganglia. (A) Immunohistochemical staining of TH and in situ hybridiza-
tion of IGF-II and GAP43 (bright field and dark field) in human fetus at week 12. Arrowheads indicate sympathetic ganglia; arrows in-
dicate paraganglia. *Area of magnification. Scale bars represent 200 μm. (B) IGF-II, SCG10, and GAP43 in situ hybridization (bright field
and dark field) and TH immunostaining in a 12-week-old fetal adrenal gland. Arrowheads indicate sympathetic ganglia. Scale bars rep-
resent 100 μm.
Figure 4. Embryonic neuroblasts express HIF-2α and IGF-II. Immunohistochemical staining of TH and HIF-2α and in situ hybridization of
IGF-II (bright field and dark field) in a week 6.5 human embryo at different magnifications. Arrowheads indicate sympathetic ganglia.
Scale bars represent 100 μm.
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HIF2A and SERPINB9 expression significantly decreased in the IGF2
knocked down cells (Figure 2B), indicating that IGF-II regulatesHIF2A
expression at conditions of low oxygen pressures.
HIF-2α and IGF2 Are Co-expressed during Normal Human
Embryonic SNS Development
IGF2 is abundantly expressed during human embryogenesis and
fetal development. However, in the developing SNS, fetal neuroblasts
(defined by, for instance, GAP43 and SCG10 expression; Figure 3, A
and B and [2]) of SNS ganglia proper and the adrenal gland do not
express IGF2 (Figure 3, A and B). In contrast, IGF2 is highly ex-
pressed in chromaffin cells of the fetal sympathetic paraganglia and
adrenal gland (Figure 3, A and B, respectively) and in SIF cells
[16]. Neuroblastoma cells derive from immature or precursor cells of
the SNS ganglionic lineage and should not express IGF2. Hence, co-
expression of IGF2 and HIF-2α in a subpopulation of immature
neuroblastoma cells in vivo and in neuroblastoma cell lines is in appar-
ent disagreement with an IGF2 negative ganglionic phenotype of the
developing SNS.
In mouse, HIF2A/Epas1 is expressed in SNS neuroblasts during
early stages (E10.5–12.5) of murine development [11], corresponding
to human embryonic weeks 4 to 6.5 [22]. Staining of a cross section
of the trunk region of a week 6.5 human embryo (the earliest human
embryonic tissue we have access to) revealed a faint HIF-2α signal
in the SNS chain ganglia defined by location and TH positivity
(Figure 4). Interestingly, at this developmental stage, the SNS chain
ganglia were IGF2 positive as well (Figure 4). Thus, in keeping with
the co-expression of these two genes in immature neuroblastoma cells,
both IGF2 and HIF-2α are expressed in neuroblasts at the 6.5-week
stage. Later during human development, HIF-2α expression dis-
appears in neuroblasts and IGF2 expression becomes restricted to
chromaffin cells (Figures 3, A and B, and 5 and [2,11,16]). In fetal
sympathetic paraganglia, however, HIF-2α expression recurs transiently
under conditions when IGF2 is persistently expressed (Figures 3, A
and B, and 5 and [10,11]).
Discussion
A cornerstone in surgical pathology is the concept that differentiation
stage and phenotype of a given subset of tumor cells are reflections of
the tissue and cell type that these tumor cells are derived from. Neuro-
blastoma is one example of this practice [23]. In old literature, this
tumor is also denoted sympathicoblastoma [24], and on the basis of
morphology, tumor location, and tumor cell phenotype, neuro-
blastomas are generally considered to derive from sympathetic neuro-
blasts or their precursors. In previous work, we defined a set of marker
genes for the ganglionic (neuroblasts), chromaffin (paraganglionic and
adrenal chromaffin cells), and SIF cell differentiation lineages of the
SNS [2]. A key marker in this scheme is IGF2, which during human
development is expressed in the chromaffin and SIF cells but not in
the sympathetic neuroblasts [16]. Unless one argues that IGF2 is
aberrantly expressed as a consequence of malignant transformation,
expression of IGF2 in neuroblastoma cells apparently contradicts a
derivation from immature neuroblasts. In this report, we present data
supporting an alternative model in which IGF2 is expressed in sym-
pathetic chain ganglia neuroblasts at an early developmental stage
(Figure 5). The IGF2 expression in neuroblastoma cells can thus be
Figure 5. HIF-2α and IGF-II are co-expressed in sympathetic neuroblasts during early human development. Sympathoadrenal progenitor
cells commit to either of three lineages, the sympathetic ganglionic, chromaffin, or SIF (not shown) cell lineages. IGF-II is expressed in
both chromaffin and sympathetic ganglionic cells during late embryogenesis, but expression becomes restricted to cells of the chromaffin
lineage during fetal development. HIF-2α can be detected in sympathetic neuroblasts of the ganglionic lineage only during late embryo-
genesis, whereas it is transiently expressed around fetal week 8.5 in chromaffin cells. Hence, IGF-II and HIF-2α are co-expressed at early
developmental stages before sympathetic ganglionic cells lose expression of both proteins. Marker gene expression for chromaffin cells
(IGF-II+, GAP-43−, TH++) and sympathetic ganglionic cells (IGF-II−, GAP-43+, TH+) as depicted. Two distinct time points are shown:
*embryonic week 6.5 and ‡fetal week 8.5.
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explained by them being arrested at such early stages of differentia-
tion. Our data further show that endogenous IGF-II drives expression
of HIF2A in neuroblastoma cells and possibly also in embryonic SNS
neuroblasts during human SNS development (Figure 5). We have
previously shown that high HIF-2α protein levels are linked to un-
favorable outcome in neuroblastoma. Here, we demonstrate that
expression of HIF2A and IGF2 in neuroblastoma tumors correlates
and that this correlation is even stronger in stage 4 and MYCN-
amplified tumors, the most aggressive neuroblastoma subtypes.
The decreased HIF2A expression seen most overtly in hypoxic cells
with downregulated IGF2 suggests that endogenously produced IGF-II
activates an autocrine stimulation mechanism leading to enhanced
HIF2A transcription. These in vitro observations are corroborated by
the strong correlation between HIF2A and IGF2 expression in a
well-defined clinical neuroblastoma material, by the co-expression of
these two genes in immature neuroblastoma cells in vivo and in neuro-
blasts of 6.5-week-old human embryonic SNS chain ganglia. Thus,
co-expression of HIF2A and IGF2 in neuroblastoma cells appears to
be associated with the immature, stem cell–like phenotype previously
described in neuroblastoma specimens and in cultured hypoxic neuro-
blastoma cells [4,9].
Numerous studies have demonstrated that HIF-2α, like HIF-1α,
protein becomes efficiently degraded in cells cultured at normoxia. The
prevailing model is that the transcriptional activity of HIF-1 and HIF-2
is mainly dependent on the availability of the oxygen-sensitive α sub-
units. Less well documented are the molecular mechanisms regulating
the abundant expression of HIF2A mRNA and protein in ganglia and
paraganglia during discrete and transient periods of SNS development
[4,10,11]. Emerging data highlight the fact that HIF2A expression is
distinctly regulated during normal development and suggest that the
HIF-2α protein does not become instantly degraded under these con-
ditions. One explanation could be that the HIF-2α positive SNS struc-
tures are hypoxic. However, the HIF-1α protein, which appears to be
a more specific marker of hypoxic cells than HIF-2α, is not detected
within these HIF-2α positive regions [10]. A similar situation seems
to exist in neuroblastoma specimens where a small subset of immature
tumor cells located at proximity to blood vessels expresses high levels
of HIF-2α but not HIF-1α [9]. In vitro, HIF2A mRNA levels are
only modestly affected by IGF2 knockdown at normoxia. This finding
indicates that additional mechanisms regulate basal HIF2A expression
in oxygenated neuroblastoma cells as well as during the discrete periods
of normal SNS development when the HIF2A gene is expressed. The
specific mechanisms that allow the HIF-2α protein to escape degradation
under non-hypoxic conditions are yet unknown, but understanding such
mechanisms might facilitate the targeting of HIF-2 transcription for
therapeutic purposes. Our data suggest that interfering with the IGF-II
signaling pathway could be one strategy for targeting the HIF-2α– or
pseudohypoxia-driven aggressive phenotype in neuroblastoma.
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Table W1. Nucleotide Sequences of Primers Used for Quantitative PCRs.
Gene Name
UBC
Forward 5′-ATTTGGGTCGCGGTTCTTG-3′
Reverse 5′-TGCCTTGACATTCTCGATGGT-3′
SDHA
Forward 5′-TGGGAACAAGAGGGCATCTG-3′
Reverse 5′-CCACCACTGCATCAAATTCATG-3′
YWHAZ
Forward 5′-ACTTTTGGTACATTGTGGCTTCAA-3′
Reverse 5′-CCGCCAGGACAAACCAGTAT-3′
HIF2A
Forward 5′-GTGCTCCCACGGCCTGTA-3′
Reverse 5′-TTGTCACACCTATGGCATATCACA-3′
IGF2
Forward 5′-CCGTGCTTCCGGACAACTT-3′
Reverse 5′-CTGCTTCCAGGTGTCATATTGG-3′
SERPINB9
Forward 5′-CTTCGGCATTTGGGAATTGT-3′
Reverse 5′-GGTCTCTCTCCGCTGACATTG-3′
